Advertisement
Australia markets open in 9 hours 17 minutes
  • ALL ORDS

    7,937.90
    +35.90 (+0.45%)
     
  • AUD/USD

    0.6488
    +0.0037 (+0.57%)
     
  • ASX 200

    7,683.50
    +34.30 (+0.45%)
     
  • OIL

    82.13
    +0.23 (+0.28%)
     
  • GOLD

    2,333.80
    -12.60 (-0.54%)
     
  • Bitcoin AUD

    103,142.01
    +885.19 (+0.87%)
     
  • CMC Crypto 200

    1,438.22
    +23.46 (+1.66%)
     

Optinose Announces Reporting Date for Third Quarter 2022 Financial Results

Optinose, Inc.
Optinose, Inc.

Conference Call and Webcast to be held November 10, 2022, at 8:00 a.m. Eastern Time

YARDLEY, Pa., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will report financial results for the third quarter 2022 and corporate updates, before market open on Thursday, November 10, 2022.

Company to Host Conference Call
Members of the Company’s leadership team will host a conference call to discuss financial results and corporate updates. The call is scheduled to start at 8:00 a.m. Eastern Time on Thursday, November 10, 2022.

ADVERTISEMENT

Participants may access the conference call live via webcast by visiting the Investors section of Optinose’s website at http://ir.optinose.com/presentations. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number and a personal PIN that can be used to access the call. In addition, a replay of the webcast will be available on the Company website for 60 days following the event.

About Optinose
Optinose is a global specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat (ENT) and allergy specialists. To learn more, please visit www.optinose.com or follow us on Twitter and LinkedIn.

Optinose Investor Contact
Jonathan Neely
jonathan.neely@optinose.com
267.521.0531